LEK-8804

LEK-8804, also known as N-(2-propynyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

LEK-8804, also known as N-(2-propynyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD. It is the derivative of ergine (lysergic acid amide; LSA) with an N-(2-propynyl) substitution on the carboxamide moiety.

The drug shows affinity for the serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors (K i = 0.56–0.6 nM, 15–60 nM, and 10–80 nM, respectively). It also shows weaker affinity for dopamine and adrenergic receptors. Based on animal behavioral studies, it is thought that LEK-8804 may act as a potent serotonin 5-HT 1A receptor full agonist and serotonin 5-HT 2A receptor antagonist.

For instance, it fully substitutes for the serotonin 5-HT 1A receptor agonist 8-OH-DPAT in rodent drug discrimination tests and produces other serotonin 5-HT 1A receptor agonist-like behavioral effects. The drug does not induce the head-twitch response, a behavioral proxy of serotonin 5-HT 2A receptor activation and psychedelic effects, in rodents.

Instead, it dose-dependently inhibits 5-hydroxytryptophan (5-HTP)- and DOI-induced head twitches. On the other hand, LEK-8804 failed to substantially block the discriminative stimulus effects of DOI in rodent drug discrimination tests.…

LEK-8804, also known as N-(2-propynyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD. It is the derivative of ergine (lysergic acid amide; LSA) with an N-(2-propynyl) substitution on the carboxamide moiety.

The drug shows affinity for the serotonin 5-HT 1A , 5-HT 2A , and 5-HT 2C receptors (K i = 0.56–0.6 nM, 15–60 nM, and 10–80 nM, respectively). It also shows weaker affinity for dopamine and adrenergic receptors. Based on animal behavioral studies, it is thought that LEK-8804 may act as a potent serotonin 5-HT 1A receptor full agonist and serotonin 5-HT 2A receptor antagonist.

For instance, it fully substitutes for the serotonin 5-HT 1A receptor agonist 8-OH-DPAT in rodent drug discrimination tests and produces other serotonin 5-HT 1A receptor agonist-like behavioral effects. The drug does not induce the head-twitch response, a behavioral proxy of serotonin 5-HT 2A receptor activation and psychedelic effects, in rodents.

Instead, it dose-dependently inhibits 5-hydroxytryptophan (5-HTP)- and DOI-induced head twitches. On the other hand, LEK-8804 failed to substantially block the discriminative stimulus effects of DOI in rodent drug discrimination tests.

These findings suggest that LEK-8804 may actually be acting merely as a serotonin 5-HT 1A receptor agonist without significant serotonin 5-HT 2A receptor antagonism. Close analogues of LEK-8804 include LEK-8842, LEK-8829, and LEK-8841, among others. LEK-8804 was first described in the scientific literature by 1994.

It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1364275120 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.